Cellectar Biosciences, Inc. — Form 10-Q Summary
Reporting period: Three and six months ended June 30, 2018. The company is a clinical-stage biopharmaceutical developer focused on its phospholipid drug conjugate platform and cancer candidates, led by CLR 131. The financial statements are unaudited.
Financial performance and position
- Revenue: The filing reports no revenue; operations are funded primarily through securities offerings and research support.
- Net loss: Q2 2018 was $2.92 million, compared with $3.12 million in Q2 2017. First-half 2018 loss was $6.40 million, versus $6.01 million in first-half 2017. Basic and diluted loss per share was $1.69 and $3.75, respectively, in 2018; comparative 2017 amounts were $2.32 and $4.72.
- Operating expenses: Q2 research and development (R&D) expense was $1.72 million, down 21% year over year; general and administrative (G&A) expense was $1.18 million, up 14%. First-half R&D was $3.80 million, down 6%; G&A was $2.56 million, up 28%.
- Cash flow: First-half cash used in operating activities was $5.73 million, compared with $5.65 million in 2017. Investing activities used $1,425; financing activities used $94,616. Cash, cash equivalents and restricted cash decreased $5.83 million.
- Liquidity and debt: At June 30, cash and cash equivalents were $4.18 million, restricted cash $55,000, and current liabilities $2.29 million; working capital was approximately $2.73 million. Total liabilities were $2.29 million, including only $3,771 of current and long-term capital lease obligations. Accumulated deficit was $90.75 million. No conventional debt balance is reported.
- Margins: Not meaningful because the company reported no revenue and operating losses.
Changes versus the prior comparable period
- Q2 net loss narrowed by about 6% year over year, while first-half net loss increased by about 6%.
- Lower R&D reflected increased NCI contract reimbursements for clinical costs and outsourced manufacturing; preclinical spending increased. Higher G&A reflected consulting, accounting, marketing and personnel costs. The company also incurred about $81,000 in one-time personnel costs related to outsourcing manufacturing.
- Cash and cash equivalents fell from $10.01 million at December 31, 2017 to $4.18 million at June 30, 2018. Headcount declined from 15 to 10.
Outlook, developments and risks
- Management stated June 30 cash alone would not fund the next 12 months, creating substantial doubt about going concern. A July 31, 2018 underwritten offering generated $16.56 million gross and approximately $14.9 million net proceeds. Management said the financing alleviated the going-concern doubt and expected cash to fund operations into Q1 2020. A pro forma June 30 balance sheet showed cash of $19.07 million.
- The offering included 1.355 million common shares, convertible preferred stock convertible into 2.785 million common shares, and warrants for 4.14 million shares. The company was still evaluating warrant classification and allocation of proceeds. These securities create significant potential dilution.
- On August 7–8, CPDC, the sole supplier of CLR 131, advised that an FDA Import Alert prevented it from supplying the drug until the alert is lifted or alternative arrangements are reached. The company expects clinical-trial enrollment delays and could not estimate their extent. The alert was not related to CLR 131 or the facility producing it.
- CLR 131 was being evaluated in Phase 1 and Phase 2 studies; pediatric Phase 1 enrollment was being initiated. Management also planned a head-and-neck cancer study for the second half of 2018. The filing describes early clinical activity, but these findings are preliminary and do not establish efficacy.
- The company depends on outside collaborators and contract organizations for research, development and manufacturing and reported no available alternate facilities for these activities. Other risks include financing needs, clinical and regulatory uncertainty, competition and execution of its development plans.
- A 1-for-10 reverse stock split took effect July 16, 2018; presented share and per-share data reflect the split retrospectively. The company also entered a lease for 3,983 square feet, with a 64-month term, approximately $783,000 of rent after abatements, and a $75,000 security deposit.
- Management reported effective disclosure controls and no significant changes in internal control over financial reporting. The filing reports no legal proceedings expected to materially affect the financial statements.
Important facts for investors to verify
- Whether the July offering proceeds and actual cash usage support the stated runway into Q1 2020.
- How quickly CPDC’s Import Alert is resolved, whether alternative supply arrangements are available, and the resulting trial-enrollment delays.
- The accounting classification and dilution implications of the Series E warrants and convertible preferred stock, alongside other outstanding warrants and options.
- Clinical-trial status, enrollment, safety and efficacy updates for CLR 131, particularly given the supply interruption and the preliminary nature of reported results.
- The company’s ongoing financing needs and execution of its outsourced manufacturing and research model.